Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis.

Deirdre M H J Ten BergeDaniel P HurkmansIlse den BestenJeroen S KlooverRon H J MathijssenReno DebetsEgbert F SmitJoachim G J V Aerts

Published in: ERJ open research (2019)

Tumour growth kinetics can be used as a clinically relevant predictor for OS in anti-PD-1-treated patients with NSCLC, and may provide additional information to RECIST measurements.

Keyphrases

small cell lung cancer
healthcare
advanced non small cell lung cancer
combination therapy
brain metastases
replacement therapy
smoking cessation
epidermal growth factor receptor